Compare DENTSPLY SIRONA Inc (XRAY) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DENTSPLY SIRONA Inc vs Xylem, Inc. — how do they compare? DENTSPLY SIRONA Inc trades at $8.73 (market cap $1.73B), while Xylem, Inc. trades at $102.17 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 13.8× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold DENTSPLY SIRONA Inc for 72 Days and Xylem, Inc. for 50 Days on average.
| XRAY | XYL | |
|---|---|---|
Market Cap | $1.73B | $23.81B |
Volume | 6,198,582 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $14.68 | $152.95 |
52-Week Low | $8.52 | $100.92 |
Typical Hold Time | 72 Days | 50 Days |
Enterprise Value | $3.80B | $25.59B |
Dividend Yield | 5.04% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent revenue growth from $5.5B in 2022 to $9.0B in 2025 and net income margin expanding to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen its industrial water solutions portfolio. XYL has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected on October 27, 2026.
Analyst consensus is mixed with 47.5% buy ratings and a $149.13 price target suggesting 46% upside. Key risks include China market weakness and increased debt from recent acquisitions. The stock offers value with reasonable P/E of 24.28 and strong cash flow generation, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
